Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This Year